Filing Flows › Voyager Therapeutics (VYGR) › Q2 2026
Voyager Therapeutics (VYGR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Voyager Therapeutics (VYGR) reported revenue of $3.2M for the second quarter 2026 (Q2 2026), -39% from a year earlier and +22% from the quarter before. Operating margin was -833.9%, net loss $24.5M (773.2% of revenue).
Voyager Therapeutics, Q2 2026: revenue $3.2M (-39% year over year), operating margin -833.9%, net loss $24.5M, operating cash flow −$25.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.2M | +22% | -39% |
| Operating profit | −$26.4M | — | — |
| Net earnings | −$24.5M | — | — |
| Operating cash flow | −$25.8M | — | — |
What changed
Revenue was $3.2M in Q2 2026, down 39% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $26.4M, an operating margin of -833.9%. Total costs fell 29% while revenue fell 39%. The quarter ended with a net loss of $24.5M, narrower than the previous quarter's $27.9M loss.
Operating cash flow was −$25.8M. Non-cash charges added back $908K of depreciation and $2.4M of share-based compensation. Working capital and other items used $4.7M.
Questions
What was Voyager Therapeutics' revenue in the second quarter 2026?
Voyager Therapeutics (VYGR) reported revenue of $3.2M for the second quarter 2026 (Q2 2026), -39% from a year earlier and +22% from the quarter before.
Was Voyager Therapeutics profitable in the second quarter 2026?
Operating loss was $26.4M (-833.9% of revenue) and net loss $24.5M.